Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

被引:196
作者
Joyce, JN [1 ]
机构
[1] Sun Hlth Res Inst, Thomas H Christopher Ctr Parkinson Dis Res, Sun City, AZ 85351 USA
关键词
striatum; caudate putamen; nucleus accumbens; Islands of Calleja; limbic;
D O I
10.1016/S0163-7258(01)00139-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cloning of the gene for the D-3 receptor and subsequent identification of its distribution in brain and pharmacology allowed for serious consideration of the possibility that it might be a target for drugs used to treat schizophrenia and Parkinson's disease (PD). That is because it is highly expressed in limbic regions of the brain, exhibits low expression in motor divisions, and has pharmacologic similarity to the D-2 receptor. Thus, antipsychotics that were presumed to block D-2 receptors also had high affinity for the D-3 receptor. Dopamine agonists used to treat the clinical symptoms of PD also have high affinity for the D-3 receptor, and two D-3 receptor-preferring agonists were found to be effective for treatment of PD. Many compounds achieving high potency and selectivity are now available, but few have reached clinical testing. Recent findings with respect to the anatomy of this receptor in human brain, altered expression in schizophrenia and PD, and biological models to study its function support the proposal that it is a target for development of drugs to alleviate symptoms in neuropsychiatric and neurologic disorders. Because of distinct aspects of regulation of the D-3 receptor, it represents a unique target for therapeutic intervention in schizophrenia without high potential for unintended side effects such as tardive dyskinesia. It may also be that D-3 receptor agonists can provide neuroprotective effects in PD and can modify clinical symptoms that D-2 receptor-preferring agonists cannot provide. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:231 / 259
页数:29
相关论文
共 289 条
[1]   Frequency of dementia in Parkinson disease [J].
Aarsland, D ;
Tandberg, E ;
Larsen, JP ;
Cummings, JL .
ARCHIVES OF NEUROLOGY, 1996, 53 (06) :538-542
[2]  
Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
[3]  
ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119
[4]   DOPAMINE RECEPTOR CHANGES IN UNTREATED AND (+)-PHNO-TREATED MPTP PARKINSONIAN PRIMATES [J].
ALEXANDER, GM ;
BRAINARD, DL ;
GORDON, SW ;
HICHENS, M ;
GROTHUSEN, JR ;
SCHWARTZMAN, RJ .
BRAIN RESEARCH, 1991, 547 (02) :181-189
[5]   ROLE OF BCL-2 IN THE BRAIN-DERIVED NEUROTROPHIC FACTOR SURVIVAL RESPONSE [J].
ALLSOPP, TE ;
KISELEV, S ;
WYATT, S ;
DAVIES, AM .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1995, 7 (06) :1266-1272
[6]   REGULATION BY DOPAMINERGIC NEUROTRANSMISSION OF DOPAMINE-D2 MESSENGER-RNA AND RECEPTOR LEVELS IN THE STRIATUM AND NUCLEUS-ACCUMBENS OF THE RAT [J].
ANGULO, JA ;
COIRINI, H ;
LEDOUX, M ;
SCHUMACHER, M .
MOLECULAR BRAIN RESEARCH, 1991, 11 (02) :161-166
[7]  
[Anonymous], 1987, LANG COGNITIVE PROC
[8]   COMPLEMENTARY POSITRON EMISSION TOMOGRAPHIC STUDIES OF THE STRIATAL DOPAMINERGIC SYSTEM IN PARKINSONS-DISEASE [J].
ANTONINI, A ;
VONTOBEL, P ;
PSYLLA, M ;
GUNTHER, I ;
MAGUIRE, PR ;
MISSIMER, J ;
LEENDERS, KL .
ARCHIVES OF NEUROLOGY, 1995, 52 (12) :1183-1190
[9]   Long-term changes of striatal dopamine D-2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [C-11]Raclopride [J].
Antonini, A ;
Schwarz, J ;
Oertel, WH ;
Pogarell, O ;
Leenders, KL .
MOVEMENT DISORDERS, 1997, 12 (01) :33-38
[10]   DOPAMINE-RECEPTOR DISTRIBUTION IN THE RAT CNS - ELUCIDATION USING ANTIPEPTIDE ANTISERA DIRECTED AGAINST D-1A AND D-3 SUBTYPES [J].
ARIANO, MA ;
SIBLEY, DR .
BRAIN RESEARCH, 1994, 649 (1-2) :95-110